На этой странице перечислены больницы направления «Онкология» (включая Prostate Cancer Treatment) в Мумбаи, Индия, включая Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai и другие.
Спросите нас о «Prostate Cancer Treatment» в Мумбаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 18 аккредитованных больниц (Онкология) в Мумбаи, Индия
Рекомендуем🇮🇳 Nanavati Super Specialty Hospital
Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).
🇮🇳 Tata Memorial Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).
🇮🇳 Apollo Hospitals, Navi Mumbai
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 512 отзывов).
🇮🇳 Gleneagles Hospital, Mumbai
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 615 отзывов).
🇮🇳 Lilavati Hospital And Research Centre
Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 724 отзывов).
🇮🇳 HCG Cancer Centre
Больница занимает 7-е место в этом списке по указанному рейтингу (4.6/5, 91 отзывов).
🇮🇳 Jaslok Hospital
Больница занимает 8-е место в этом списке по указанному рейтингу (4.6/5, 129 отзывов).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 183 отзывов).
🇮🇳 Medicover Hospital, Navi Mumbai
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 143 отзывов).
🇮🇳 KIMS Hospitals, Thane
Больница занимает 11-е место в этом списке по указанному рейтингу (4.6/5, 58 отзывов).
🇮🇳 Fortis Hospital, Mulund
Больница занимает 12-е место в этом списке по указанному рейтингу (4.5/5, 79 отзывов).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Больница занимает 13-е место в этом списке по указанному рейтингу (4.5/5, 83 отзывов).
🇮🇳 Wockhardt Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.4/5, 30 отзывов).
🇮🇳 Wockhardt Super Speciality Hospital
Больница занимает 15-е место в этом списке по указанному рейтингу (4.4/5, 48 отзывов).
🇮🇳 S. L. Raheja Hospital
Больница занимает 16-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Saifee Hospital
Больница занимает 17-е место в этом списке по указанному рейтингу (4.3/5, 97 отзывов).
🇮🇳 Dr. L H Hiranandani Hospital
Больница занимает 18-е место в этом списке по указанному рейтингу (4.3/5, 141 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Онкология» указано среди её специализаций и она находится в Мумбаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «prostate cancer treatment» в Мумбаи, Индия?
Выбор подходящей больницы для «prostate cancer treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Prostate Cancer Treatment»
Prostate cancer treatment encompasses a spectrum of precision oncology interventions—from robotic-assisted radical prostatectomy and intensity-modulated radiotherapy (IMRT) to hormonal therapy, brachytherapy, and novel androgen receptor pathway inhibitors—achieving 5-year survival rates exceeding 95% for localized disease and 70–80% for locally advanced stages when managed at high-volume centers. India and the UAE have emerged as premier destinations for international patients seeking world-class prostate cancer care at significantly reduced costs, with access to JCI- and NABH/DHA-accredited hospitals staffed by oncologists trained at leading Western institutions. GAF Healthcare connects patients to these centers through end-to-end care coordination, covering diagnostics, multidisciplinary tumor board review, treatment, and post-treatment follow-up—without compromising clinical outcomes. Hospital Stay: 3–7 days (varies by modality: robotic prostatectomy typically 2–3 days; radiotherapy is outpatient over 4–8 weeks) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (post-surgery fit-to-fly is typically 3–4 weeks; radiotherapy patients may fly within 1–2 weeks of completing treatment, subject to oncologist clearance) • Success Rate: 95%+ (localized disease, 5-year relative survival); 70–80% (locally advanced/metastatic, with modern systemic therapy)
Clinical Overview
Prostate cancer arises from the malignant transformation of glandular epithelial cells in the prostate, a walnut-sized exocrine gland situated inferior to the bladder and anterior to the rectum. It is the second most common cancer in men globally, with adenocarcinoma accounting for over 95% of cases. Disease behavior ranges from indolent, low-risk tumors that may be managed with active surveillance to aggressive, high-grade cancers that require multimodal systemic intervention. Risk stratification is conducted using validated classification systems—most notably the D'Amico risk criteria and the NCCN (National Comprehensive Cancer Network) risk groupings—incorporating PSA (prostate-specific antigen) levels, clinical T-stage, and Gleason score (now reported as Grade Groups 1–5 per the 2014 ISUP consensus). Physiologically, untreated or advanced prostate cancer can invade the seminal vesicles, bladder neck, and neurovascular bundles, leading to urinary obstruction, sexual dysfunction, and, in metastatic disease, skeletal pain and pathological fractures due to osteoblastic bone involvement. Lymph node metastasis typically follows predictable pelvic nodal pathways, while distant spread most commonly involves the axial skeleton. Castration-sensitive versus castration-resistant disease states dictate the choice of androgen deprivation therapy (ADT) combinations and next-generation agents such as enzalutamide, apalutamide, darolutamide, abiraterone acetate, and PARP inhibitors (e.g., olaparib for BRCA1/2-mutated tumors). The global standard of care now mandates a multidisciplinary tumor board (MTB) approach, integrating urological oncology, radiation oncology, medical oncology, pathology, nuclear medicine, and palliative care. Leading hospitals in India (Mumbai, Delhi, Bangalore, Chennai, Hyderabad) and the UAE (Dubai, Abu Dhabi) adhere to NCCN, EAU (European Association of Urology), and ESMO guidelines, offering diagnostic precision through multiparametric MRI (mpMRI), PSMA PET-CT, and fusion-guided targeted biopsy—ensuring accurate staging and individualized treatment planning.
Who is a Candidate?
• Men diagnosed with prostate adenocarcinoma confirmed by transrectal ultrasound (TRUS)-guided biopsy or MRI-fusion targeted biopsy, with pathology graded using the Gleason/Grade Group system • Localized disease (T1–T2, N0, M0) candidates for curative intent: robotic-assisted radical prostatectomy (RARP), external beam radiotherapy (EBRT/IMRT/VMAT), or low-dose-rate (LDR) brachytherapy • Locally advanced disease (T3–T4, N1, M0) candidates for combined modality: EBRT + long-term ADT, with or without docetaxel intensification per STAMPEDE trial data • Metastatic castration-sensitive prostate cancer (mCSPC) patients eligible for ADT + novel hormonal agents (abiraterone + prednisone, enzalutamide, apalutamide) or ADT + docetaxel chemotherapy • Castration-resistant prostate cancer (mCRPC) patients for PARP inhibitors (olaparib, rucaparib) if BRCA1/2 or HRR gene-mutated; or lutetium-177 PSMA radioligand therapy (Lu-177 PSMA-617) per VISION trial data • Active surveillance candidates: Grade Group 1 (Gleason 3+3=6), PSA <10 ng/mL, clinical stage ≤T2a, with ≤3 positive biopsy cores and ≤50% cancer involvement in any core • Required pre-treatment diagnostics: Serum PSA, free/total PSA ratio, complete blood count (CBC), comprehensive metabolic panel (CMP), testosterone level, multiparametric MRI (mpMRI) of prostate and pelvis, PSMA PET-CT or conventional bone scan + CT chest/abdomen/pelvis for staging, 12-core systematic biopsy + targeted biopsy (MRI-fusion), and genetic testing (germline BRCA1/2, ATM, CDK12) for high-risk and metastatic disease • Contraindications and caution flags: Severe cardiopulmonary comorbidities (ASA class IV) contraindicating general anesthesia for surgery; prior pelvic radiotherapy limiting retreatment options; inflammatory bowel disease (relative contraindication to prostate brachytherapy and EBRT); untreated coagulopathy; patient preference after shared decision-making against invasive treatment
Treatment Options & Approaches
ACTIVE SURVEILLANCE For Grade Group 1 and select Grade Group 2 low-risk tumors, active surveillance (AS) follows structured PSA monitoring every 3–6 months, repeat prostate MRI annually, and confirmatory biopsy at 12–18 months. This approach avoids treatment-related morbidity while ensuring early intervention if reclassification occurs. AS is the recommended standard per EAU and NCCN guidelines for eligible men. ROBOTIC-ASSISTED RADICAL PROSTATECTOMY (RARP) The da Vinci Surgical System (Xi or SP platform) enables nerve-sparing radical prostatectomy with 3D high-definition visualization, tremor filtration, and wristed instrumentation. RARP offers significantly reduced blood loss (<200 mL versus ~500–800 mL in open surgery), lower transfusion rates, shorter catheterization time (7–10 days), and faster continence recovery versus open retropubic prostatectomy. Bilateral nerve-sparing techniques—when oncologically feasible—preserve erectile function in 50–70% of preoperatively potent patients at 12–24 months. Pelvic lymph node dissection (PLND) extent is guided by Briganti nomogram risk assessment. Extended PLND (ePLND) is recommended for intermediate- and high-risk disease. EXTERNAL BEAM RADIOTHERAPY (EBRT) Modern radiotherapy platforms include: • IMRT (Intensity-Modulated Radiation Therapy): Sculpts dose around the prostate while sparing rectum and bladder. • VMAT (Volumetric Modulated Arc Therapy): Faster delivery (2–4 minutes per fraction) with superior dose conformality. • Stereotactic Body Radiotherapy (SBRT) / CyberKnife / SABR: Ultra-hypofractionation delivering 35–40 Gy in 5 fractions over 1–2 weeks (PACE-B trial validated), equivalent oncologic outcomes to conventional fractionation with higher convenience. • Image-Guided Radiotherapy (IGRT): Daily fiducial marker or electromagnetic transponder (Calypso) tracking ensures millimeter precision in prostate localization. • Hydrogel SpaceOAR implantation: Biodegradable rectal spacer placed prior to RT to reduce rectal dose, significantly lowering rates of radiation proctitis. BRACHYTHERAPY • Low-Dose-Rate (LDR) brachytherapy: Permanent implantation of iodine-125 or palladium-103 seeds under TRUS guidance; suitable for low-risk and select intermediate-risk disease. • High-Dose-Rate (HDR) brachytherapy: Temporary iridium-192 source delivering focal boost doses, often combined with EBRT for high-risk localized disease. SYSTEMIC AND HORMONAL THERAPIES • Androgen Deprivation Therapy (ADT): LHRH agonists (leuprolide, goserelin) or antagonists (degarelix, relugolix—oral, with faster testosterone suppression and reduced cardiovascular events vs. LHRH agonists). • Novel Androgen Receptor Signaling Inhibitors (ARSIs): Enzalutamide, apalutamide, darolutamide (for nmCRPC); abiraterone acetate + prednisone (CYP17A1 inhibitor, blocks adrenal androgen synthesis). • Chemotherapy: Docetaxel (75 mg/m² q21 days × 6 cycles) for high-volume mCSPC (CHAARTED/STAMPEDE) or mCRPC; cabazitaxel for post-docetaxel mCRPC. • PARP Inhibitors: Olaparib, rucaparib, niraparib for BRCA1/2 or HRR-mutated mCRPC (PROfound, TRITON2 trial data). • Radioligand Therapy (RLT): Lutetium-177 PSMA-617 (Pluvicto/Lutathera platform)—binds prostate-specific membrane antigen (PSMA) on tumor cells, delivering targeted beta radiation. Approved for PSMA-positive mCRPC post-ARSI and taxane therapy (VISION trial: 38% reduction in death risk). Available at select centers in India and the UAE. • Immunotherapy: Sipuleucel-T (autologous cellular immunotherapy) where available; pembrolizumab for MSI-H/dMMR prostate tumors. FOCAL THERAPIES (SELECT CENTERS) • High-Intensity Focused Ultrasound (HIFU): Ablative therapy for localized, organ-confined disease using focused ultrasound energy; minimally invasive with catheter-free recovery in most cases. • Cryotherapy: Focal or whole-gland cryoablation using argon gas probes under TRUS guidance. • Focal Laser Ablation (FLA): MRI-guided laser interstitial thermal therapy for focal disease. MULTIDISCIPLINARY TUMOR BOARD (MTB) All complex cases at GAF Healthcare-partnered hospitals are reviewed by an MTB comprising urological oncology, radiation oncology, medical oncology, nuclear medicine, pathology, and supportive care—mirroring the standard at Mayo Clinic and MD Anderson Cancer Center.
Восстановление
STEP 1 — PRE-ARRIVAL CONSULTATION (Week 1–2, Remote) Patients share existing diagnostic reports (PSA, biopsy pathology, MRI, CT/bone scan) with GAF Healthcare's clinical coordinators. A virtual consultation is arranged with the treating uro-oncologist and/or radiation oncologist within 48–72 hours. The multidisciplinary tumor board reviews the case and provides a preliminary treatment plan with cost estimate before the patient books travel. STEP 2 — ARRIVAL & COMPREHENSIVE STAGING (Day 1–3) On arrival, the patient is received at the airport by a GAF Healthcare coordinator and transferred to the hospital or partner accommodation. Repeat or confirmatory diagnostics are performed if needed: PSMA PET-CT, mpMRI, updated PSA, testosterone, and biomarker testing. A formal tumor board meeting is conducted, the treatment plan is finalized with the patient and family, and informed consent is obtained. STEP 3A — SURGICAL PATHWAY (Robotic Prostatectomy): Day 3–5 Patient is admitted 1 day prior. Pre-anesthetic assessment, bowel prep, and Foley catheter placement are completed. RARP is performed under general anesthesia (2–4 hours). The patient is typically mobilized within 12–24 hours. Drain removal occurs Day 1–2 post-op. Hospital discharge is Day 2–3. Urinary catheter remains for 7–10 days post-discharge. Pathology report (including margin status, lymph node status) is available within 5–7 days. STEP 3B — RADIOTHERAPY PATHWAY (SBRT/IMRT): Weeks 1–8 For SBRT: 5 outpatient fractions over 1.5–2 weeks (e.g., every other day). SpaceOAR hydrogel placement and fiducial marker insertion are performed as a day procedure 1 week prior to RT start. For conventional IMRT: 28–39 fractions over 5.5–7.5 weeks, Monday–Friday. Patients remain ambulatory throughout and may stay in partner accommodation near the cancer center. STEP 3C — SYSTEMIC THERAPY INITIATION (mCSPC/mCRPC): Day 1–7 ADT injection, oral ARSI, or chemotherapy cycle 1 is administered. Education on medication schedules, side-effect monitoring, and follow-up labs is provided. International prescriptions and supply coordination for continued therapy at home are arranged by GAF Healthcare. STEP 4 — POST-TREATMENT MONITORING & REHABILITATION (Weeks 1–4 in-country) Post-prostatectomy: Pelvic floor physiotherapy (Kegel exercises) is initiated in-hospital and continued with video-guided sessions. Erectile rehabilitation program (phosphodiesterase-5 inhibitors, vacuum erection device) begins at 4–6 weeks post-op. PSA nadir is checked at 6–8 weeks post-surgery. Post-radiotherapy: Urinary and bowel symptom monitoring using IPSS and CTCAE grading. Fatigue management and nutritional support provided. STEP 5 — FIT-TO-FLY CLEARANCE & DEPARTURE (Week 3–6) The treating oncologist issues a medical fitness-to-fly certificate. For post-prostatectomy patients, DVT prophylaxis guidance (compression stockings, low-molecular-weight heparin if required) is provided. Complete discharge summary, pathology reports, operative notes, and long-haul flight precautions are prepared in English and the patient's preferred language. STEP 6 — REMOTE FOLLOW-UP (Months 1–24) GAF Healthcare facilitates telemedicine follow-ups at 6 weeks, 3 months, 6 months, and annually. PSA surveillance reports are reviewed by the treating oncologist remotely. Biopathological findings, recurrence risk, and adjuvant therapy recommendations are communicated to the patient's home oncologist via a formal clinical handover report.
Возможные риски
Prostate cancer treatment, while highly effective, carries modality-specific risks that patients must understand before committing to a therapeutic pathway. Robotic-assisted radical prostatectomy (RARP) carries risks of urinary incontinence (stress incontinence in 5–20% at 12 months, with most recovering continence by 18–24 months), erectile dysfunction (rates vary from 20–70% depending on nerve-sparing extent and pre-operative function), anastomotic leak, lymphocele formation following pelvic lymph node dissection, thromboembolic events (DVT/PE, mitigated by early ambulation and LMWH prophylaxis), and a <1% risk of intraoperative vascular or rectal injury. Biochemical recurrence (rising PSA post-prostatectomy, defined as PSA ≥0.2 ng/mL on two consecutive measurements) occurs in approximately 20–40% of patients at 10 years depending on pathological risk features, and may require salvage radiotherapy or hormonal therapy. External beam radiotherapy risks include radiation proctitis (rectal bleeding, urgency—Grade ≥2 in 5–10% with modern IMRT/SpaceOAR), radiation cystitis (dysuria, hematuria), urethral stricture (2–5%), and secondary malignancy risk over decades (very low absolute risk). Brachytherapy can cause acute urinary retention (10–20%), urinary symptoms peaking at 3–6 months post-implant, and rarely rectal fistula. Androgen deprivation therapy (ADT) carries a well-documented systemic side-effect profile: hot flashes (>60%), loss of libido and erectile dysfunction (near-universal), decreased bone mineral density with fracture risk (DEXA monitoring and bisphosphonate/denosumab prophylaxis are standard), metabolic syndrome, cardiovascular risk acceleration (particularly with LHRH agonists versus antagonists like relugolix), anemia, and cognitive changes. Novel ARSIs add fall and fracture risk, hypertension, and hepatotoxicity monitoring requirements. Docetaxel chemotherapy carries neutropenic fever risk (G-CSF prophylaxis recommended), peripheral neuropathy, alopecia, and fatigue. Lutetium-177 PSMA RLT can cause dry mouth (xerostomia), fatigue, nausea, and transient myelosuppression. Patients are stratified by performance status (ECOG 0–2), comorbidity burden, and molecular profile to individualize risk-benefit assessment at the tumor board level.
Почему GAF Healthcare
GAF Healthcare provides comprehensive non-medical support to ensure that international patients and their accompanying family members experience a seamless, stress-free journey from their home country to India or the UAE and back. VISA & ENTRY DOCUMENTATION For India: GAF Healthcare's coordination team assists patients in obtaining the e-Medical Visa (e-MV) and e-Medical Attendant Visa for up to two accompanying family members. The e-Medical Visa is typically processed within 3–5 business days, is valid for 60 days with triple entry, and requires a formal letter from the treating hospital (which GAF Healthcare procures on the patient's behalf). Express processing is available for urgent cases. For the UAE (Dubai/Abu Dhabi): Citizens of over 50 countries (including the UK, EU, USA, Canada, Australia, and GCC nations) receive visa-on-arrival or visa-free entry for 30–90 days. Patients from other regions can obtain a UAE medical treatment visa sponsored by the hospital, with GAF Healthcare coordinating documentation. The UAE's proximity to Africa, South Asia, and Eastern Europe makes it a highly accessible treatment hub with no visa complexity for most patient nationalities. AIRPORT TRANSFERS & IN-COUNTRY MOBILITY Dedicated, air-conditioned medical transport is arranged for all airport-to-hospital and hospital-to-accommodation transfers. Wheelchair-accessible vehicles are available upon request. For radiotherapy patients undergoing 4–8 weeks of outpatient treatment, GAF Healthcare provides daily scheduled transport between accommodation and the cancer center. ACCOMMODATION GAF Healthcare maintains partnerships with serviced apartments and hotel properties adjacent to its network hospitals in Delhi, Mumbai, Chennai, Bangalore, Hyderabad (India) and Dubai, Abu Dhabi (UAE). Accommodation packages for patients and their attendants range from budget-friendly to luxury options, with meal delivery, housekeeping, and 24-hour concierge support. In-hospital attendant accommodation (cot/bed in patient room) is arranged at no additional cost at most partner hospitals. CLINICAL TRANSLATION & INTERPRETATION Dedicated medical interpreters fluent in Arabic, Russian, French, Swahili, Bengali, Urdu, Amharic, and other languages are available in-person or via secure video link for all clinical consultations, informed consent discussions, and discharge briefings. Written discharge summaries, drug prescriptions, and follow-up plans are provided in both English and the patient's preferred language. INSURANCE, BILLING & FINANCIAL TRANSPARENCY GAF Healthcare provides upfront cost estimates broken down by diagnostic, procedural, and accommodation components before the patient travels. Assistance with international health insurance claim documentation is provided. Transparent, itemized invoices are issued in USD. No hidden fees or post-treatment billing surprises—a commitment backed by GAF Healthcare's patient charter. CONTINUITY OF CARE Before discharge, GAF Healthcare's clinical team prepares a comprehensive medical handover report for the patient's home oncologist or GP, including treatment summary, pathology, imaging, operative notes, current medications, and a structured follow-up schedule. Telemedicine follow-up appointments with the treating specialist are coordinated at 6 weeks, 3 months, and 6 months post-treatment.
Частые вопросы о процедуре «Prostate Cancer Treatment»
What is the cost of Prostate Cancer Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after Prostate Cancer Treatment?
What is the success rate of Prostate Cancer Treatment at GAF Healthcare partner hospitals?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «prostate cancer treatment» в Мумбаи, Индия
Найдите лучшие больницы для «prostate cancer treatment» в Мумбаи, Индия
На этой странице представлено 18 больниц в Мумбаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Prostate Cancer Treatment» в Мумбаи, Индия
Сколько больниц направления «Онкология» представлено в Мумбаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Мумбаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Prostate Cancer Treatment» в Мумбаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.